LWAC
JAZZ icon

Laurel Wealth Advisors (California)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,505
Closed -$212K – 304
2016
Q1 		$212K Hold
1,505
– – 0.11% 225
2015
Q4 		$212K Buy
+1,505
New +$209K 0.11% 220

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Laurel Wealth Advisors (California)'s JAZZ Position: Q2 2016 in Review

Laurel Wealth Advisors (California) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2016, closing a stake of 1,505 shares — an estimated $212K sold.

Laurel Wealth Advisors (California) first reported a position in JAZZ in Q4 2015 and held it in 2 quarters. The position peaked at $212K in Q1 2016. 366 funds tracked by Wall St. Rank hold JAZZ as of Q2 2016.

  • Laurel Wealth Advisors (California) reported no remaining Jazz Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Laurel Wealth Advisors (California) sold 1,505 Jazz Pharmaceuticals shares in Q2 2016, an estimated $212K.
  • Laurel Wealth Advisors (California) first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Laurel Wealth Advisors (California)'s Jazz Pharmaceuticals position peaked at $212K in Q1 2016.
  • 366 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2016.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q2 2016, filed 11 Aug 2016.